Polaryx Therapeutics (PLYX) Net Cash Flow (2025 - 2026)
Polaryx Therapeutics' (PLYX) quarterly Net Cash Flow came in at -$1.3 million in Q2 2026, down 49.49% year-over-year from -$2.6 million in Q2 2025, and up 36.57% quarter-over-quarter from -$2.1 million in Q1 2026.
Powered by 
Analysis
Polaryx Therapeutics (PLYX) Net Cash Flow (2025 - 2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported Net Cash Flow for 2 consecutive years, with -$1.3 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Net Cash Flow fell 49.49% year-over-year to -$1.3 million in Q2 2026; TTM through Jun 2026 was -$4.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $522000.0, down 88.63% from the prior year.
- Net Cash Flow was -$1.3 million for Q2 2026 at Polaryx Therapeutics, up from -$2.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at -$459000.0 in Q1 2025 and troughed at -$2.1 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -183.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -170.75 Mn |
| 10 | Polaryx Therapeutics | 97.52 Mn | 85.98 Mn | - | -1.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.33 Mn |
| Mar 31, 2026 | -2.10 Mn |
| Jun 30, 2025 | -891,000.00 |
| Mar 31, 2025 | -459,000.00 |